Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

N/A
6(100.0%)
6Total
N/A(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT06608823Not ApplicableRecruiting

ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™

Role: lead

NCT06594705Not ApplicableRecruiting

The JenaValve ALIGN-AR LVAD Registry

Role: lead

NCT05536310Not Yet Recruiting

TAVIS Registry - Trilogy Heart Valve System for Management of Patients With Aortic Valve Disease

Role: lead

NCT02732691Not ApplicableUnknown

JENAVALVE AS EFS TRIAL: Pericardial TAVR Aortic Stenosis Study

Role: lead

NCT02732704Not ApplicableActive Not Recruiting

THE ALIGN-AR EFS TRIAL: JenaValve Pericardial TAVR Aortic Regurgitation Study

Role: lead

NCT04415047Not ApplicableActive Not Recruiting

The JenaValve ALIGN-AR Pivotal Trial

Role: lead

NCT01598844Completed

JUPITER Study: Transapical Aortic Valve Implantation for Aortic Regurgitation

Role: lead

NCT02818959Not ApplicableTerminated

First in Man Study of the JenaValve TAVI Plus System Transfemoral

Role: lead

All 8 trials loaded